Hepatitis Virus Patents (Class 424/149.1)
-
Patent number: 7105303Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.Type: GrantFiled: August 13, 2001Date of Patent: September 12, 2006Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
-
Patent number: 7101551Abstract: The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.Type: GrantFiled: February 13, 2001Date of Patent: September 5, 2006Assignees: Mitsubishi Pharma Corporation, Japan as Represented by Director General of Agency of National Institute of Infectious DiseasesInventors: Seima Itami, Tatsurou Shibui, Makoto Seki, Yoshihisa Yotsumoto, Yoshiharu Matsuura, Tatsuo Miyamura
-
Patent number: 7052830Abstract: Novel hepatitis C virus (HCV) polypetides are provided which are not encoded by the standard HCV open reading frame. These alternate reading frame polypeptides are useful, inter alia, in vaccine compositions, in diagnosing HCV infection, and as therapeutic targets.Type: GrantFiled: June 9, 1999Date of Patent: May 30, 2006Inventors: Andrea D. Branch, Jose L. Walewski, Decherd D. Stump
-
Patent number: 7026457Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.Type: GrantFiled: October 10, 2001Date of Patent: April 11, 2006Assignee: Innogenetics N.V.Inventors: Geert Maertens, Fons Bosman, Guy De Martynoff, Marie Ange Buyse
-
Patent number: 6951646Abstract: Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.Type: GrantFiled: July 20, 1999Date of Patent: October 4, 2005Assignees: Genmab A/S, Institut National de la Sante et de la Recherche Medicale (I.N.S.E.R.M.)Inventors: Christian Reiter, Francois Habersetzer, Anne Fournillier, Christian Trepo, Claude Desgranges, Genevieve Inchauspe
-
Patent number: 6930176Abstract: The invention describes the identification of major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the isolation and characterization of neutralizing chimpanzee monoclonal antibodies reactive to the neutralization site and the use of these antibodies in the diagnosis, treatment and prevention of HEV.Type: GrantFiled: November 30, 2000Date of Patent: August 16, 2005Assignee: The United States of America as represented by the Secretary of the Department of Health & Human ServicesInventors: Darren Schofield, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 6924362Abstract: The present invention describes the identification and characterization of five human HC E1-specific monoclonal antibodies isolated from a phage display library and their use in the diagnosis, treatment, and prevention of HCV in mammals, preferably humans.Type: GrantFiled: November 30, 2001Date of Patent: August 2, 2005Assignee: The United States of America as represented by the Department of Health & Human ServicesInventors: Darren Schofield, Suzanne U. Emerson, Robert H. Purcell, Harvey J. Alter
-
Patent number: 6884417Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.Type: GrantFiled: May 15, 2001Date of Patent: April 26, 2005Assignee: The Scripps Research InstituteInventors: Theo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
-
Publication number: 20040141998Abstract: Disclosed are methods of stimulating in a subject an immune response to an antigen to which the immune response is targeted. This method includes the step of administering to the subject a binding agent which binds a surface receptor of an antigen-presenting cell, in some instances without being blocked substantially by the natural ligand for the surface receptor, and an antigen to which the immune response is targeted, in a physiologically acceptable medium to the subject. Also disclosed are molecular complexes including the binding agent coupled to an antigen.Type: ApplicationFiled: July 15, 2003Publication date: July 22, 2004Inventors: Jean Loup Romet-Lemonne, Michael W. Fanger, Paul M. Guyre, Edmund J. Gosselin
-
Patent number: 6747136Abstract: The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molecules are useful in specific binding assays, affinity purification schemes and pharmaceutical compositions for the prevention and treatment of HCV infection in mammalian subjects. The invention thus relates to novel human monoclonal antibodies specific for HCV E2 antigen, fragments of such monoclonal antibodies, polypeptides having structure and function substantially homologous to antigen-binding sites obtained from such monoclonal antibodies, nucleic acid molecules encoding those polypeptides, and expression vectors comprising the nucleic acid molecules.Type: GrantFiled: April 17, 1997Date of Patent: June 8, 2004Assignee: Karolinska Innovations ABInventors: Mats Axel Atterdag Persson, Tobias Erik Allander
-
Patent number: 6685931Abstract: The hepatoprotective effect of IL-10 is described, in particular, the use of interleukin-10 in the treatment of liver damage (e.g. fibrosis or cirrhosis) in a difficult-to-treat patient afflicted with chronic hepatitis C virus infection who has failed to respond to, or achieve a sustained virologic response to an anti-HCV therapy(e.g., interferon-&agr; in combination with ribavirin).Type: GrantFiled: December 20, 1999Date of Patent: February 3, 2004Assignee: Schering CorporationInventors: Paul C. Grint, David R. Nelson, Gary L. Davis
-
Patent number: 6680053Abstract: The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombinant vector.Type: GrantFiled: May 29, 2001Date of Patent: January 20, 2004Assignee: Yuhan CorporationInventors: Jong Wook Lee, In Young Ko, Heui Keun Kang, Jung Hyun Nam, Moo Young Song, Hyung Jin Moon, Tae Hun Song
-
Patent number: 6610295Abstract: HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary. The gH protein is encoded by DNA in the HindIII L fragment lying between 228 and 2456 bases from the L/D boundary. The genes have been incorporated in recombinant vaccinia vectors and expressed in host animals to raise HCMV-neutralizing antibody, thereby indicating vaccine potential. The glycoproteins can also be used in a variety of different ways, as vaccines or in the production, purification or detection of HCMV antibody.Type: GrantFiled: May 26, 1995Date of Patent: August 26, 2003Assignee: Cogent LimitedInventors: Geoffrey Lilley Smith, Martin Patrick Cranage, Barclay George Barrell
-
Patent number: 6565849Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.Type: GrantFiled: March 2, 2001Date of Patent: May 20, 2003Assignee: MedImmune, Inc.Inventor: Scott Koenig
-
Patent number: 6538114Abstract: The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molecules are useful in specific binding assays, affinity purification schemes and pharmaceutical compositions for the prevention and treatment of HCV infection in mammalian subjects. The invention thus relates to novel human monoclonal antibodies specific for HCV E2 antigen, fragments of such monoclonal antibodies, polypeptides having structure and function substantially homologous to antigen-binding sites obtained from such monoclonal antibodies, nucleic acid molecules encoding those polypeptides, and expression vectors comprising the nucleic acid molecules.Type: GrantFiled: April 19, 1996Date of Patent: March 25, 2003Assignee: Karolina Innovations ABInventors: Mats Axel Atterdag Persson, Tobias Erik Allander
-
Patent number: 6472159Abstract: The present invention provides a method of inducing an immune response to a subunit antigen in a non-responding subject by administering to the subject a composition comprising the subunit antigen and an amphipathic compound. A preferred antigen is a hepatitis B antigen, and a preferred amphipathic compound is DC-chol.Type: GrantFiled: April 16, 2001Date of Patent: October 29, 2002Assignee: Aventis Pasteur S.A.Inventors: Anne Darbouret, Florence Brunel, Jorge Ronco
-
Publication number: 20020086020Abstract: This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.Type: ApplicationFiled: January 10, 2002Publication date: July 4, 2002Applicant: OSEL, INC.Inventor: Peter P. Lee
-
Publication number: 20020028214Abstract: A drug which protects individuals against hepatitis C virus (HCV) is made of HCV hyperimmune globulins, which guarantee a substantial hyperimmunity against HCV thanks to a substantial hyperconcentration of virus C neutralizing antibodies. This hyperconcentration is obtained from blood of a large number of antiHCV positive blood donors. The material used for the preparation of the HCV hyperimmune globulins is made of up to 100 % of antiHCV positive blood units.Type: ApplicationFiled: August 26, 1998Publication date: March 7, 2002Inventor: MARCELLO PIAZZA
-
Patent number: 6254867Abstract: Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various uses of said antibodies in the prevention and treatment of HBV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HBVsAg antibodies are engrafted into normal strains of mice which were lethally irradiated and radioprotected with SCID bone marrow. After immunization of such chimeric mice with HBVsAg, human cells are obtained from the mice spleens and fused in vitro with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HBVsAg.Type: GrantFiled: December 10, 1998Date of Patent: July 3, 2001Assignees: Yeda Research & Development Co. Ltd, XTL Biopharmaceuticals LtdInventors: Yair Reisner, Shlomo Dagan